News
-
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
-
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
-
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
-
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
-
ONL Therapeutics Names Connie Chang as Chief Operating Officer
-
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
-
ONL Therapeutics featured on the OIS Retina Podcast
-
ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204
-
ONL Therapeutics Announces First-in-human Clinical Study With ONL1204